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ABSTRACT 
Background and Aim: In patients with HCV-related cirrhosis, a SVR may lead to cirrhosis 
regression. Whether histological changes translate into prevention of long-term complications, 
particularly hepatocellular carcinoma (HCC) is still unknown. This was investigated in a cohort of 
histological cirrhotics who had been prospectively followed-up for 10 years after the achievement 
of a SVR to IFN. Methods: 38 SVR cirrhotics who underwent a liver biopsy (LB) 5 years post-
SVR were prospectively followed to assess the impact of cirrhosis regression on clinical endpoints. 
Results: During a follow-up of 86 (30-96) months from LB, no patients developed clinical 
decompensation, whilst 5 (13%) developed HCC after 79 (7-88) months. The 8-year cumulative 
probability of HCC was 17%, without differences between patients with or without cirrhosis 
regression [19% (95% CI 6-50%) vs. 14% (95% CI 4-44%), p=0.88]. Patients who developed or did 
not an HCC had similar rates of residual cirrhosis (p=1.0), collagen content (p=0.48), METAVIR 
activity (p=0.34), portal inflammation (p=0.06) and steatosis (p=0.17). At baseline, patients who 
developed an HCC had higher γGT (HR 1.03, 95% CI 1.00-1.06; p=0.014) and glucose (HR 1.02, 
95% CI 1.00-1.02; p=0.012) values; moreover, they had increased Forns Score (HR 12.8, 95% CI 
1.14-143.9; p=0.039), Lok Index (HR 6.24, 95% CI 1.03-37.6; p=0.046) and PLF (HR 19.3, 95% 
CI 1.72-217.6; p=0.016) values. One regressor died of lung cancer. The 8-year cumulative survival 
probability was 97%, independently on cirrhosis regression (96% vs. 100%, p=1.0) or HCC (100% 
vs. 97%, p=1.0). Conclusions: Post-SVR cirrhosis regression does not prevent HCC occurrence.  
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Bullet Points  
 Cirrhotic patients who achieve an SVR to anti-HCV regimens should remain on regular HCC 
surveillance since it has been demonstrated that the risk of liver cancer is not fully abrogated 
by viral eradication 
 Whether regression of cirrhosis following an SVR may prevent liver-related complications is 
still unknown 
 In our cohort of cirrhotic patients who achieved an SVR through IFN-based regimens, HCC 
occurred at low rates independently on post-SVR cirrhosis regression 
 Neither clinical parameters, post-SVR histological features or non-invasive tests were able to 




The advent of safe and effective direct-acting antivirals (DAA) has revolutionized treatment of 
chronic hepatitis C raising the bar of virus eradication above 90% in hepatitis C virus (HCV) 
cirrhotics who have longer been the hardest patients to be cured with interferon (IFN) 1. In the IFN 
era, patients with advanced liver disease who achieved HCV eradication appeared to be partially 
protected against the risk of clinical decompensation and hepatocellular carcinoma (HCC) 
development. The identification of risk factors associated with HCC development in HCV cirrhotics 
with a sustained virological response (SVR) could allow to design individualized surveillance 
schedules, hence containing healthcare costs. In a single-center study in France, end-stage 
complications of HCV were fully prevented in the subgroup of SVR patients with histologically 
documented regressed cirrhosis 2. Indeed, cirrhosis regression was not infrequent among IFN-
responders, with rates from 24% to 100% 2-16.   
Mitigating the impact of cirrhosis regression in SVR patients, however, is suboptimal accuracy of  
liver biopsy (LB) to establish cirrhosis regression, owing to the 25% risk of fibrosis 
misclassification of small liver tissue cores 17. This coupled with the fact that the French study 
correlated the histological regression of cirrhosis with combined endpoints including liver failure, 
bleeding and HCC, prompted us to prospectively evaluate the clinical outcome of a cohort of 38 
cirrhotics, 23 (61%) of whom with histological cirrhosis regression 5 years after the achievement of 
an SVR 18. Regressors and non regressors were then subjected to surveillance for HCC with 6-





MATERIAL AND METHODS 
Patient population 
This is a long-term follow-up study of previously published Italian-French cooperative study 
conducted on 38 HCV cirrhotics who underwent paired LB, before and after the achievement of an 
SVR to IFN-based regimens 18. All patients were prospectively followed-up after post-SVR LB 
(baseline); hepatitis B virus (HBV) or human immunodeficiency virus (HIV) coinfections as well as 
alcohol consumption, which were previously excluded 18, were confirmed during follow-up. 
Patients underwent 6-month clinical follow-up with blood test and US. Data entry was completed 
on 31 March 2017. Informed consent was obtained from each patient included in the study. The 
protocol was approved by the Institutional Board of our Department (Ethical Committee Milan 
Area 2) and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. 
 
Biochemical assays 
The following normal values were used: alanine aminotransferase (ALT) < 19 U/l for females and 
<30 U/l for males 19; γglutamil-transferase (γGT) <36 U/l for females and <60 U/l for males; 
cholesterol <200 mg/dL, high density lipoprotein (HDL) cholesterol >60 mg/dL; triglycerides < 150 
mg/dL; alpha-fetoprotein (αFP) <7 μg/ml.    
 
Histological assessment 
Post-SVR LB were performed with 16G Menghini-like semi-automatic needles 18. Post-treatment 
fibrosis was staged according to the METAVIR scoring system 20, and cirrhosis regression was 
defined as previously published as METAVIR <F4 18. Residual fibrosis was quantitatively assessed 
(%) by morphometry. Residual activity was classified according to both METAVIR and Ishak 
classifications 21,22, and immunohistochemistry [citokeratine-7 (CK7), glutamine synthetase (GS), 
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cytochrome P450 2E1 (CYP2E1), α-smooth muscle actin (αSMA), and CD34] was carried-out 
semi-quantitatively using a three grade system (0, 1, 2) 18 (see results). When possible, histology 
was obtained to confirm HCC, as well as from extra-lesion tissue.  
 
Non-invasive assessment of fibrosis 
Patients underwent post-SVR non-invasive assessment of residual liver fibrosis 23,24, which was 
concomitant to LB. Transient elastography (TE) was performed as already described 25, liver 
stiffness measurement (LSM) being expressed in kilopascal (kPa). The following serological 
indirect and direct markers of liver fibrosis (Non Invasive Tests, NITs) were tested according to 
their formula, as previously published 24: APRI, CDS, FIB-4, FibroQ, Forns Score, GUCI, King’s 
Score, Lok Index, PLF, and ELF. Reference cut-offs for cirrhosis in viremic patients were APRI > 
1.5, CDS > 8, FIB-4 > 3.25, FibroQ > 2.6, Forns Score > 6.9, GUCI > 0.26, King’s Score > 16.7, 
Lok Index > 0.5 and PLF > 2.98 (Supplementary Table 1).  
 
Study endpoints 
The primary endpoint of the study was the relationship between post-SVR cirrhosis regression and 
the risk of developing liver-related events [i.e. HCC, liver failure or varices-related gastrointestinal 
(GI)-bleeding]. Hepatocellular carcinoma was diagnosed according to international criteria 26-29. 
Liver failure was defined as an episode of ascites, jaundice or hepatic encephalopathy. In case 
multiple events occurred in a single subject, only the first event contributed to outcome measure. 
Secondary and tertiary endpoints were the relationship between other post-SVR histological 




In all patients, follow-up started at the time of post-SVR LB (baseline) 18,23,24 and patients were 
censored at the time of their first liver-related complication or at their last follow-up date. 
Categorical variables were reported as frequencies (percentages) and continuous variables as 
median (range). Categorical variables were compared using the χ2 or the Fisher’s exact tests; 
continuous variables were compared using the Student t-test, the Mann-Whitney U-test or the 
Kruskall-Wallis test, when appropriate. All tests were two-sided and used a significance level of 
0.05. 
The Kaplan-Meier method was used to assess the cumulative incidence of clinical events during 
follow-up. Cox regression analysis was used to identify baseline variables associated with HCC 
during follow-up. Variables with a threshold value of <0.05 were considered statistically 
significant. Results are expressed as adjusted hazard ratio (HR) and their 95% confidence intervals 
(C.I.). Data handling and analysis were performed with StataView package (SAS Institute Inc., 
Cary, NC).  
 
RESULTS  
Patients included in the study were males (65%), with a median age of 66 (46-75) years; SVR was 
achieved 61 (48-104) months before. Prevalence of BMI >25 (55%), diabetes (10.5%), 
hypercholesterolemia (55%) and hypertriglyceridemia (13%) (Table 1) were similar to those 
recorded at the time of SVR achievement (p-values 0.36, 0.36, 0.62 and 1.0, respectively). Cirrhosis 
regression was documented in 23 (61%) patients (Table 1). Patients with and without cirrhosis 
regression were similar in terms of demographic and clinical features (Table 1), although F4 
patients had a higher prevalence of hypertriglyceridemia (p=0.07) and higher levels of fasting 
glucose (p=0.08), which however did not reach statistical significance. Moreover, patients with 
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cirrhosis regression had lower LSM values when compared to non regressors (9.1 kPa vs. 12.9 kPa, 
p=0.004) (Table 1), but were similar according to most of the NITs (Supplementary Table 2)  
After LB, all patients were adherent to 6-month surveillance, and were followed-up for 86 (30-96) 
months, without any differences between patients with and without cirrhosis regression [88 (74-96) 
vs. 83 (30-95), p=0.52]. During follow-up, most of them showed persistently normal values of both 
ALT and γGT (71% and 68%, respectively).  
 
Liver-related events 
No episodes of clinical decompensation or GI-bleeding were recorded, whilst HCC developed in 5 
(13%) patients. Median time to HCC development was 79 (7-88) months. The 8-year cumulative 
probability of HCC was 17% (95% CI: 7% - 39%), with an annual estimated incidence rate of 1.2% 
(Figure 1A). 
At the time of HCC development, patients (80% males) had a median age of 71 (62-74) years, with 
BMI value of 26 (25-28). Most of them had persistently normal ALT and γGT values (80% and 
60%, respectively). Diabetes was present in 2 (40%), hypercholesterolemia in 3 (60%) and 
hypertriglyceridemia in 1 (20%) of them. All patients had compensated liver diseases (CPT A5), 
with a median LSM of 9.3 (8.5-36.3), without differences between patients with and without 
cirrhosis regression [F<4 vs. F4: 9.3 (5.4-36.6) vs. 10.2 (8.5-11.8), p=1.0]. Alpha-fetoprotein was 
normal in most of them (80%), with a median value of 4.2 (2.6-57) ng/ml. In all cases, HCC was 
single, sized 22 (19-30) mm, non-metastatic; therefore curative approaches were offered (4 RFTA, 
1 resection). Histology was available for three patients at the time of HCC treatment (Figure 2), 
which confirmed post-SVR LB fibrosis stage (2 F3, 1 F4) (see below). 
At baseline, patients who developed or did not develop a HCC were similar according to the most 
important demographic and clinical features, although the formers displayed higher γGT values 
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(p=0.04) and an increased prevalence of diabetes (p=0.07) (Table 2). No differences in HCC 
development were observed in patients with and without esophageal varices at baseline (13% vs. 
25%, p=0.49)  
At univariate analysis, fasting glucose (HR 1.02, 95% CI 1.00-1.02; p=0.012) and γGT values (HR 
1.03, 95% CI 1.00-1.06; p=0.014) were significantly associated with HCC development, whereas 
diabetes (HR 5.62, 95% CI 0.93-33.9; p=0.06) and steatosis (HR 0.99, 95% CI: 1.05-0.09; p=0.092) 
were close to statistical significance (Table 3). 
Patients who did develop an HCC were also similar to those who did not in most of the baseline 
histological features, as assessed at the time of post-SVR LB. In patients who developed HCC 
advanced stages of residual fibrosis were frequent (p=0.06) although the prevalence of cirrhosis was 
similar in patients with or without HCC (40% vs. 40%, p= 1.0) (Table 4). The 8-year cumulative 
probability of HCC was similar in patients with or without cirrhosis regression (p=0.88). However, 
the two patients with residual cirrhosis developed HCC earlier than those who achieved cirrhosis 
regression (7 and 27 months vs. 79, 80 and 88 months from LB) (Figure 1B). In addition, no 
differences were observed in terms of steatosis, residual collagen content or improvement in the 
area of fibrosis as compared to pre-treatment values. Similarly, immunohistochemistry did not 
differ between the two groups.      
Baseline LSM did not differ among patients who subsequently developed or not an HCC (12.6 kPa 
vs. 9.8 kPa, p=0.78) (Table 2). Nevertheless, although we did not observe any difference for most 
of the NITs according to the presence of HCC, patients who developed liver cancer had higher post-
SVR values of Lok Index (p=0.05), whilst Forns Score (p=0.09) and PLF (p=0.06) were close to 
statistical significance (Table 5). At univariate analysis, the following NITs were associated with an 
increased risk of HCC: Forns Score > 6.9 (p=0.039), Lok Index > 0.5 (p=0.046) and PLF > 2.98 
(p=0.016) (Table 3).  
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Non-liver related events 
Extra-hepatic malignancies were the only non-liver related events recorded in 3 (7.8%) patients, all 




During 86 (30-96) months after LB, one patient died of lung cancer (71 months). The 8-year 
cumulative survival was 97%, and was not influenced by cirrhosis regression (96% vs. 100%, 
p=1.0) or HCC development (100% vs. 97%, p=1.0). Post-LB follow-up was similar in patients 
who did develop or not an HCC [HCC 90 (30-96) vs. non-HCC 86 (74-95) months, p=0.70].  
One patient was lost during follow-up, 3 months after HCC treatment (RFTA), i.e. 30 months after 
post-SVR LB.  
 
DISCUSSION 
This prospective study demonstrates that the risk of HCC was not fully abrogated in patients who, 
following an SVR to IFN, had histologically documented regression of cirrhosis, which was defined 
according to previously published studies 4,5,12,18. Cirrhosis regression was documented in 61% of 
patients in our cohort after a median follow up of 5-year post-SVR 18, whereas in the subsequent 
follow-up of 86 months liver cancer was the only liver-related complication. The fact that patients 
who had cirrhosis at the onset of IFN-based therapies face a life-long, residual risk of developing 
HCC after achieving an SVR, is well documented 30,31. In our study, despite the small sample size 
of the cohort and the low incidence of HCC, the analysis of the correlation between histological and 
clinical features and risk of HCC during a 10-year follow-up, showed that, at variance with the 
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French study, cirrhosis regression did not prevent HCC development 2. In that study, the only 
adverse outcomes among SVR patients with residual cirrhosis were three cases of HCC and one GI-
bleeding. This is not a trivial point, since our findings contradict expert recommendations that 
suggest to drop surveillance in SVR patients when post-SVR cirrhosis regression is documented 
32,33, at the same time reinforcing AASLD and EASL recommendation for continued surveillance of 
SVR patients, independently from cirrhosis regression 1,34.  
Not unexpectedly, the rates of HCC in our SVR patients were quite low (1.2%) and similar in both 
regressors and non regressors (p=0.88), telling us that the dissociation between HCC risk and 
cirrhosis regression supports the need for life-long surveillance in SVR patients with a diagnosis of 
cirrhosis before antiviral therapy. At the time of surgical treatment of HCC, cirrhosis regression 
could be further confirmed histologically.  
Interestingly, patients with and without HCC were similar for most of the histological features 
assessed at post-SVR LB, thus preventing us to find any characteristics associated with an increased 
risk of liver cancer after virus eradication. Of note, HCC was not predicted by persistence of 
steatosis, residual portal inflammation and collagen content amount. Moreover, we found no 
differences according to several immunohistochemical markers, when comparing patients who did 
or did not develop a HCC, thus suggesting that persistence of most of the microscopic features of 
cirrhosis (i.e. sinusoidal capillarization, metabolic zonation or hepatic stellate cells activation) have 
no role in favouring liver cancer development. This is a novelty, since to the best of our knowledge 
no studies have investigated the correlation between immunohistochemical markers and the risk of 
liver-complication among SVR patients.   
Apart from histological findings, while patients maintained persistently normal values of serum 
transaminases and γGT with respect to pre-treatment, HCC mostly occurred in patients with 
metabolic syndrome, including diabetes. We previously reported an inverse relationship between 
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γGT values and rates of cirrhosis regression after the achievement of an SVR 18. Our findings are in 
line with previous studies in HCV patients with an SVR to IFN 35-37 where metabolic disorders, 
including diabetes, were associated with a residual risk of HCC.   
Finally, we correlated post-SVR NITs values with the residual risk of HCC in our cohort and found 
that patients who developed a liver cancer displayed higher baseline values of Forns Score, Lok 
Index and PLF. Among them, Forns Score includes γGT, age and cholesterol which have been 
previously demonstrated to be associated with an increased risk of HCC after an SVR. This is an 
important finding, since scarce data exist on the correlation between post-SVR NIT values and 
residual risk of HCC in non-viremic patients 38,39. Different serum biomarkers have been 
retrospectively analyzed, in all cases without any correlation with histology, and studies provided 
discordant results. In fact, Toyoda and colleagues 38 found that low pre-treatment Forns Score 
values were protective against the risk of liver cancer, whereas none of the 20 tests analyzed in the 
study by Thandassery et al. reached any significant predictive value at multivariate analysis 39. On 
the contrary, we found that Forns Score, Lok Index and PLF values above the viremic F4 cut-off 
were associated with an increased risk of HCC. Although these data have been obtained in a much 
selected cohort, thus preventing us from assessing NITs real predictive values, we think that this 
aspect need further external large validation.       
We acknowledge that our study does have some limitations related to our selection criteria and the 
small number of end points, i.e. HCC. The latter, however, is the inevitable consequence of 
prospectively investigating the cohort composed by IFN-cured cirrhotics who accepted to repeat a 
liver biopsy after achieving a SVR, an event that reduces the risk of HCC. Noticeably, compliance 
with the study protocol was optimal as one patient was lost during follow-up, only and this 
happened after achieving HCC diagnosis. Finally, although the definition of cirrhosis regression we 
used is constraining and we could not exclude sampling errors 40 , we did refer to the same criteria 
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used in our previously published studies 18,23,24, which however have been widely accepted in most 
of the other studies demonstrating cirrhosis and fibrosis regression among SVR patients treated with 
IFN 4,5,12. Whether a less restrictive definition of cirrhosis regression should be used when 
analyzing the relationship between residual fibrosis and  liver-related events could be matter of 
debate. In fact, in our study no HCC were observed among patients staged F1-F2 (i.e. METAVIR 
decrease >1 stage), thus suggesting that a less stringent criteria to define cirrhosis regression could 
be useful in identifying those patients more likely to remain free from liver cancer. This would be in 
line with what previously reported in the French study by Mallet and colleagues 2. 
In conclusion, the finding that HCC developed also in SVR patients with cirrhosis regression (F3) 
greatly attenuates the need for refining the management of SVR patients in relation to residual liver 
fibrosis. The fact that regressed patients developed HCC later than non regressors deserves 
attention, as it might suggest the presence of causes of liver disease progression other than HCV. 
However, two out of three patients with a liver cancer showed regression to METAVIR F3 in the 
absence of any additional cause of liver disease. We wish to think that the risk of HCC in such 
regressors is the consequence of long lasting exposure of liver cells to direct and indirect 
carcinogenetic effects of HCV, as clearly documented in more than one experimental study 41. 
Our finding that patient survival was not influenced by either residual fibrosis stage or HCC 
occurrence (one patient died of non-liver related complication, only) is in line with a recently 
published multicentre study in Italy 30,31 where SVR cirrhotics showed comparable survival rates as 
the general population 31. 
We acknowledge that our study was to some extent weakened by the strict selection criteria we 
adopted; yet, at the same time it provides robust information to refine surveillance of SVR patients, 
i.e. not to interrupt surveillance in SVR patients with an initial diagnosis of cirrhosis.  
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In conclusion, our finding that the risk of liver cancer among SVR cirrhotics was not fully 
abrogated in regressed patients fully supports the recommendation of international societies for life-
long surveillance strategies, independently on the stage of post-SVR liver disease. Although 
deserving further validation, the finding of persistently high post-SVR values of certain NITs in 
patients with liver cancer might be useful to tailor surveillance strategies in cured patient, 
independently on histological assessment of residual fibrosis. At the moment, our results reinforce 
futility of repeated liver biopsies and investigations with non-invasive tests in SVR patients lacking 
other than HCV risk factors for liver disease.  
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FIGURE LEGEND  
 
Figure 1. Cumulative probability of HCC in the entire cohort (1A) and according to residual 
fibrosis stage (1B). 
 
Figure 2. Resected liver specimen from a patient who developed an HCC 80 months after post-
SVR LB (i.e. 180 months after SVR) showing subcapsular well-demarcated nodule (A; H&E 5x), 
corresponding to moderately differentiated trabecular HCC (B; H&E 200x); non-tumoral liver 
parenchyma demonstrates largely incomplete nodular structure (C; Masson’s Trichrome 5x) with 
portal-to-portal complete and incomplete fibrous septa and peri-septal steatosis, without necro-
inflammatory activity (D; Masson’s Trichrome 5x). 
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Age, years * 66 (46-75) 65 (56-72) 66 (46-75) 0.98 
Males, n 24 (65%) 9 (60%) 15 (63%) 1.0 
BMI, Kg/m2 * 24.5 (19.9-34.3) 24.9 (19.9-34.3) 24.5 (20.1-30.4) 0.71 
Anti-HBc, n 17 (48.5%) 9/14 (64%) 8/21 (38%) 0.18 
Diabetes, n 4 (10.5%) 2 (13%) 2 (9%) 1.0 
Disease duration, months * 186 (60-633) 131 (60-449) 215 (60-633) 0.75 
METAVIR F0/F1/F2/F3/F4, n 0/2/7/14/15 0/0/0/0/15 0/2/7/14/0 <0.0001 
TE value, kPa * 9.8 (4.4-34.3) 12.9 (7.0-31.6) 9.1 (4.4-34.3) 0.004 
PLT, 103/mm3 * 202 (85-401) 200 (110-283) 206 (85-401) 0.75 
ALT, U/l * 21 (9-53) 20 (9-53) 22 (12-47) 0.70 
Normal ALT, n 27 (71%) 10 (67%) 17 (74%) 0.74 
γGT, U/l * 28 (11-109) 36 (11-99) 23 (13-109) 0.62 
Albumin, mg/dl * 4.6 (3.7-5.3) 4.6 (3.7-5.1) 5.0 (4.4-5.3) 0.10 
INR * 1.01 (0.86-1.10) 1.0 (0.87-1.10) 1.0 (0.86-1.1) 0.98 
Bilirubin, mg/dl * 0.5 (0.4-2.4) 0.5 (0.3-1.3) 1.0 (0.3-2.4) 0.71 
Cholesterol, mg/dl * 210 (154-265) 206 (169-258) 215 (154-265) 0.46 
Cholesterol > 200 mg/dl, n 21 (55%) 8 (53%) 13 (57%) 1.0 
HDL < 60 mg/dl, n 23 (61%) 9 (60%) 14 (61%) 1.0 
Triglycerides, mg/dl *  112 (13-211) 110 (61-211) 113 (13-200) 0.23 
Triglycerides > 150 mg/dl, n 5 (13%) 4 (27%) 1 (4%) 0.07 
Glucose, mg/dl * 89 (71-297) 91 (71-297) 86 (71-149) 0.08 
 
* Median (range) 
BMI: body mass index; TE: transient elastography; PLT: platelets; ALT: alanine amino-transferase; γGT: 
gamma-glutamil transferase; INR: international normalized ratio; HDL: high density lipoprotein cholesterol; 
LB: liver biopsy; HCC: hepatocellular carcinoma 
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Age, years * 65 (55-70) 66 (46-75) 0.48 
Males, n  4 (80%) 20 (61%) 0.63 
BMI, Kg/m2 * 25.0 (24.6-27.6) 25.3 (19.9-34.3) 0.87 
Anti-HBc, n 3 (60%) 14 (42%) 0.64 
Diabetes, n 2 (40%) 2 (6%) 0.07 
Disease duration, months * 189 (54-237) 183 (6.-633) 0.91 
TE value, kPa * 12.6 (5.7-34.3) 9.8 (4.4-31.6) 0.78 
PLT, mm3 * 193 (85-313) 204 (103-401) 0.91 
ALT, U/l * 20 (10-46) 22 (9-53) 0.88 
Normal ALT, n  4 (67%) 23 (72%) 1.0 
γGT, U/l * 74 (27-109) 23 (11-99) 0.04 
Albumin, mg/dl * 4.7 (3.7-5.3) 4.6 (3.7-5.2) 0.50 
INR * 1.03 (1.0-1.08) 1.0 (0.86-1.1) 0.62 
Bilirubin, mg/dl * 0.7 (0.5-0.8) 0.5 (0.3-2.5) 0.62 
Cholesterol, mg/dl * 215 (180-234) 206 (154-265) 0.19 
Cholesterol > 200 mg/dl, n 3 (60%) 18 (55%) 1.0 
HDL < 60 mg/dl, n 4 (80%) 19 (58%) 0.63 
Triglycerides, mg/dl *  120 (93-166) 106 (13-211) 0.49 
Triglycerides > 150 mg/dl, n 1 (20%) 4 (12%) 0.53 
Fasting glucose, mg/dl * 99 (85-297) 88 (71-220) 0.12 
Fasting glucose > 126 mg/dl, n 2 (40%) 2 (6%) 0.07 
 
* Median (range) 
HCC: hepatocellular carcinoma; BMI: body mass index; TE: transient elastography; PLT: platelets; ALT: 
alanine amino-transferase; γGT: gamma-glutamil transferase; INR: international normalized ratio; HDL: 
high density lipoprotein cholesterol; LB: liver biopsy; HCC: hepatocellular carcinoma 
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Table 3. Baseline variables associated with HCC development at univariate analysis 
 
Features HR 95% C.I. p-value 
γGT, U/l  1.03 1.00 – 1.06 0.014 
Fasting glucose, mg/dL 1.02 1.00 – 1.02 0.012 
Diabetes 5.62 0.93 – 33.9 0.06 
Steatosis 0.99 1.05 – 0.09 0.09 
Forns Score > 6.9 12.8 1.14 – 143.9 0.039 
Lok Index > 0.5 6.24 1.03 – 37.6 0.046 
PLF > 2.98 19.3 1.72 – 217.6 0.016 
 
HCC: hepatocellular carcinoma; γGT: gamma-glutamil transferase; PLF: predictive liver fibrosis 
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Core specimen, mm * 30 (25-30) 30 (10-50) 0.36 
Fibrosis stage (METAVIR), n 
     0 
     1 
     2 
     3 














Activity (METAVIR), n 
     0 
     1 










Portal inflammation, n 
     0 
     1 
     2 
     3 














Steatosis >5%, n  2 (40%) 4 (12%) 0.17 
Steatosis, n 
    <5 
    5-33 
    34-66 












Area of fibrosis, % * 2.4 (1.7-5.9) 2.3 (0.6-15.1) 0.48 
Δ area of fibrosis, % * ± 63.5 (37.2-75.4) 74.4 (-84.1-93.8) 0.38 
Immunohistochemistry, n (%) # 
    CK7 IHBCs 
    CK7 HPCs 
    GS 
    CD34 
    αSMA 























* Median (range) 
± Δ area of fibrosis: calculate as the difference between baseline (post-SVR) LB and pre-treatment LB area of 
fibrosis (18)  
# Immunostaining expressed as presence (>0) at LB: CD34 available in 37, αSMA in 36, CYP2E1 (>1) in 33 
patients 
HCC: hepatocellular carcinoma; CK7: Cytokeratin 7; IHBCs: Intermediate hepatobiliary cells; HPCs: Hepatic 
progenitor cells; GS: Glutamine synthetase; αSMA: anti-smooth muscle actin; CYP: Cytochrome P      
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Table 5. Baseline NIT values according to HCC development 
 





APRI* 0.3 (0.2-0.9) 0.3 (0.2-0.8) 0.65 
APRI >1.5 0 0 1.00 
CDS 5.0 (3.0-6.0) 5.0 (3.0-7.0) 0.93 
CDS >8 0 0 1.00 
FIB-4 2.1 (1.0-2.4) 1.7 (0.8-3.7) 0.87 
FIB-4 >3.25 0 2 (6%) 1.00 
FIBRO-Q 4.0 (2.0-6.8) 3.8 (1.5-7.9) 0.65 
FIBRO-Q >2.6 4 (80%) 25 (76%) 1.00 
Forns Score* 6.5 (4.5-8.5) 4.9 (4.0-8.0) 0.19 
Forns Score >6.9* 2 (50%) 3 (10%) 0.09 
GUCI 0.4 (0.3-0.9) 0.4 (0.2-0.9) 0.62 
GUCI >0.26 4 (80%) 25 (76%) 1.00 
King’s 7.6 (5.9-16.9) 7.7 (3.8-20.6) 0.68 
King’s >16.7 1 (20%) 2 (6%) 0.35 
Lok Index 0.5 (0.1-0.6) 0.4 (0.1-0.7) 0.31 
Lok Index >0.5 3 (60%) 5 (15%) 0.05 
PLF** 2.8 (2.2-5.0) 2.6 (1.7-4.7) 0.35 
PLF >2.98* 2 (50%) 2 (10%) 0.06 
ELF** 9.4 (8.6-9.6) 8.4 (6.8-10.0) 0.08 
      
Results are expressed as median values (range) or n (%) 
* Calculated in 4 patients with HCC and 29 patients w/o HCC; ** Calculated in 4 patients with HCC and 
25 patients w/o HCC. 
NIT: non invasive test; HCC: hepatocellular carcinoma. 
 28 
Supplementary Table 1. NIT formula  
 
APRI  
AST to Platelet Ratio 
AST levels (x ULN)/platelets count (103/l) x 100 
CDS  
Cirrhosis Discriminate Score 
Calculated by summing the scores awarded for the following laboratory 
results 
INR: 0 <1.1; 1 1.1-1.4; 2 >1.4 
ALT/AST: 0 >1.7; 1 1.7-1.2; 2 1.19-0.6; 3 <0.6 
PLT/mm3 0>340; 1 34.-280; 2 279-220; 3 219-160; 4 159-100; 5 99-40; 6 
<40 
FIB-4 [age (yr) x AST (U/l)]/[PLT (109/l)] x [ALT (U/l)1/2]  
FibroQ [(10 x age (yr)) x AST (U/l) x PT INR]/[PLT (109/l) x ALT (U/l)] 
Forns Score 7.811 – 3.131 x ln [PLT (109/l)] x 0.781 ln [γGT (U/l)] + 3.467 x ln [age 
(yr)] – 0.014 [cholesterol (mg/dl)] 
GUCI  
Goteborg University Cirrhosis Index 
(AST/ULN) x INR x 100/PLT (109/l) 
King Score Age (yr) x AST (U/l) x INR/PLT (109/l) 
Lok Index -5.56 – 0.0089 x PLT (103/mm) + 1.26 x AST/ALT ratio + 5.27 x INR 
PLF 
Predicted Liver Fibrosis 
0.956 + 0.084 x TE – 0.004 x King Score + 0.124 x Forns Score + 0.202 x 
APRI score 
ELF 
Enhanced Liver Fibrosis 
-7.412 + [ln(HA)_0.681] + [ln(PIIINP) - 0.775] + [ln(TIMP-1) - 0.494] + 
10 
 
AST: aspartate aminotransferase; ULN: upper limit of normal; INR: International Normalized Ratio; ALT: 
alanine aminotransferase; PLT: platelets; yr: years; PT: protrombin time; γGT: gamma-glutamil transferase; TE: 
transient elastography; HA: hyaluronic acid; PIIINP: N-terminal propeptide of type III collagen; TIMP: tissue 
inhibitor of metalloprotease 
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Supplementary Table 2. Baseline NITs # according to post-SVR fibrosis stage and reference cut-offs for 
the diagnosis of cirrhosis 24  
 
Test Reference 




















CDS  > 8 5 (2-7) 5 (2-6) 5 (3-7) 0.49 
FIB-4 > 3.25 1.7 (0.8-3.7) 1.7 (0.8-2.7) 1.7 (1.1-3.7) 0.38 
FibroQ > 2.6 3.9 (1.5-7.9) 3.9 (1.5-6.3) 4.0 (1.7-7.9) 0.26 
Forns Score* > 6.9 5.1 (3.1-8.5) 5.1 (3.1-8.5) 5.3 (4.0-8.0) 0.83 
GUCI Index > 0.26 0.4 (0.2-1.0) 0.4 (0.18-0.95) 0.4 (0.21-0.90) 0.56 
King Score  > 16.7 7.7 (3.8-20.6) 7.7 (3.8-16.9) 7.7 (4.7-20.6) 0.48 
Lok Index > 0.5 0.4 (0.1-0.7) 0.4 (0.1-0.6) 0.4 (0.1-0.7) 0.24 
PLF* > 2.98 2.5 (1.7-5.0) 2.5 (1.7-5.0) 2.5 (2.2-4.7) 0.01 
ELF** >9.3, >9.8, 
>10.3, >11.3 
8.6 (6.8-10.0) 8.6 (7.0-10.0) 8.4 (6.8-9.9) 0.70 
 
# Results are reported as median (range) values  
* Calculated in 33 patients for whom valid TE assessments and/or cholesterol values were available 
** Calculated in 29 patients 
 
 
